Compare EVN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVN | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.0M | 462.8M |
| IPO Year | 1998 | 2010 |
| Metric | EVN | PACB |
|---|---|---|
| Price | $11.10 | $1.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 71.5K | ★ 5.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $10.09 | $1.09 |
| 52 Week High | $11.23 | $2.73 |
| Indicator | EVN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 68.11 | 62.84 |
| Support Level | $10.81 | $1.46 |
| Resistance Level | $11.17 | $1.78 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 98.08 | 73.49 |
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.